Roche tossed out Spark Therapeutics' choroideremia gene therapy SPK-7001, also known as RG6367, as well as nonalcoholic steatohepatitis (NASH) ...
https://www.google.com/url?rct=j&sa=t&url=https://www.fiercebiotech.com/biotech/roche-lets-go-etro-dumping-phase-3-crohn-s-prospect-18-months-after-posting-weak-colitis&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNG8-X6BB8irFKFkLD4ed9PJTUjfeQ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.